merck

FDA approval came on May 13 and Merck & Co. Inc. (NYSE: MRK) will launch Victrelis this month, Deutsche Bank reports. “Labeling was generally very favorable for boceprevir, with no major exclusions or restrictions (other than for DDIs), and potential RGT options for most patients -- in our...

According to Citi, Merck (NYSE: MRK) reported strong 1Q11 results with EPS of $0.92 (+11%), +$0.07 above estimate and +$0.06 above the Street. Citi said that revenues came in $224M above projection at $11.58B (+1%) vs. 11.36B & the Street $11.37B (+$0.04 EPS impact). “The performance was...

On April 5, 2010, Merck (NYSE: MRK) announced that they are acquiring Inspire Pharmaceuticals (NASDAQ: ISPH) for approximately $430 million, LifeTech Capital reports. “Merck stated goal is to strengthen their ophthalmic portfolio with Inspire's AZASITE (azithromycin ophthalmic solution) for the...

Citi is maintaining its EPS estimates on Merck (NYSE: MRK). “As expected, Merck returned the worldwide rights to betrixaban, an oral factor Xa inhibitor (anticoagulant) for patients with atrial fibrillation (AF), back to Portola after a pipeline portfolio review,” Citi writes. “We view the...

Jefferies & Company said that it has updated its Merck & Company, Inc. (NYSE: MRK) model to incorporate the strong Q3'10 operational results despite lower than consensus revenues. “Management tightened the 2010E EPS guidance upwards to $3.31 - $3.39 while maintaining the previous revenue...

Jim Cramer was recently on CNBC talking short term market movement; he voiced his opinion that the recent sell off is technical and quite healthy (many, myself included agree). He stated that near term momentum is with the defensive names as large players rotate out of high beta names and look for...